Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 17/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pobilukast SCHEMBL6437479 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| Pobilukast SCHEMBL29473536 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| Pobilukast SCHEMBL9508139 | 0.99 | CYSLTR2 (0.98) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| Pobilukast SCHEMBL9508133 | 0.99 | CYSLTR2 (0.98) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| Pobilukast SCHEMBL635997 | 0.94 | CYSLTR2 (0.89) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| SCHEMBL9395589 | 0.89 | CYSLTR2 (0.81) | CYSLTR2CYSLTR1 | |
| SCHEMBL27262084 | 0.89 | CYSLTR2 (0.81) | CYSLTR2CYSLTR1 | |
| SCHEMBL9395596 | 0.89 | CYSLTR2 (0.81) | CYSLTR2CYSLTR1 | |
| SCHEMBL9301491 | 0.88 | CYSLTR2 (0.78) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| SCHEMBL8925768 | 0.88 | CYSLTR2 (0.78) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2169 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023075715-A1 | A PHARMACEUTICAL FORMULATION INCLUDING LEUKOTRIENE RECEPTOR ANTAGONISTS AND/OR LEUKOTRIENE SYNTHESIS INHIBITORS COMBINED WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2023-05-04 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20220105082-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD (CN) | 2022-04-07 | — | — | US | claimed |
| US-11273162-B2 | Compositions and methods targeting HCN channels for breathing therapeutics | MISSISSIPPI STATE UNIVERSITY (US) | 2022-03-15 | — | — | US | claimed |
| EP-3908284-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | Jiangyin Mucocare Pharmaceutical Co., Ltd (CN) | 2021-11-17 | — | — | EP | claimed |
| CN-113613657-A | Novel formulations containing leukotriene receptor antagonists | 江阴优培尔康药业有限公司 | 2021-11-05 | — | — | CN | claimed |
| WO-2020143744-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | JIANGYIN MUCOCARE PHARMACEUTICAL CO., LTD. (CN) | 2020-07-16 | — | — | WO | claimed |
| US-20190111061-A1 | COMPOSITIONS AND METHODS TARGETING HCN CHANNELS FOR BREATHING THERAPEUTICS | MISSISSIPPI STATE UNIVERSITY (US) | 2019-04-18 | — | — | US | claimed |
| WO-2017173458-A1 | COMPOSITIONS AND METHODS TARGETING HCN CHANNELS FOR BREATHING THERAPEUTICS | SWIDERSKI CYPRIANNA (US) | 2017-10-05 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2003020219-A2 | AEROSOLIZED DECONGESTANTS FOR THE TREATMENT OF SINUSITIS | SINUSPHARMA INC (US) | 2003-03-13 | — | — | WO | claimed |
| US-5288900-A | Crystallization of optical isomers of leukotriene antagonists using (R)-4-nitro-α-methylbenezenemethonamine | SMITHKLINE BEECHAM CORPORATION (US) | 1994-02-22 | — | — | US | claimed |
| EP-0563048-A1 | AEROSOL FORMULATIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-06 | — | — | EP | claimed |
| EP-0552254-A1 | CRYSTALLIZATION OF OPTICAL ISOMERS OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-28 | — | — | EP | claimed |
| WO-1992011236-A1 | AEROSOL FORMULATIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-07-09 | — | — | WO | claimed |
| WO-1992005151-A1 | CRYSTALLIZATION OF OPTICAL ISOMERS OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-04-02 | — | — | WO | claimed |
| EP-0202759-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-20 | — | — | EP | claimed |
| US-4874792-A | RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-17 | — | — | US | claimed |
| US-4820719-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-11 | — | — | US | claimed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | claimed |